29A Stock Overview
A bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. More details
| Snowflake Score | |
|---|---|
| Valuation | 6/6 |
| Future Growth | 1/6 |
| Past Performance | 4/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Amphastar Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$20.84 |
| 52 Week High | US$49.70 |
| 52 Week Low | US$20.60 |
| Beta | 0.79 |
| 1 Month Change | -12.33% |
| 3 Month Change | -42.86% |
| 1 Year Change | -43.38% |
| 3 Year Change | -46.84% |
| 5 Year Change | 38.93% |
| Change since IPO | 98.44% |
Recent News & Updates
Recent updates
Shareholder Returns
| 29A | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | -7.7% | 2.1% | 2.4% |
| 1Y | -43.4% | -23.4% | 2.0% |
Return vs Industry: 29A underperformed the German Pharmaceuticals industry which returned -23.4% over the past year.
Return vs Market: 29A underperformed the German Market which returned 2% over the past year.
Price Volatility
| 29A volatility | |
|---|---|
| 29A Average Weekly Movement | 6.6% |
| Pharmaceuticals Industry Average Movement | 4.9% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in DE Market | 12.3% |
| 10% least volatile stocks in DE Market | 3.1% |
Stable Share Price: 29A has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: 29A's weekly volatility (7%) has been stable over the past year.
Community vs My Fair Value
Select a narrative for quick price alerts from the community, or create your own.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1996 | 2,028 | Jack Zhang | www.amphastar.com |
Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company also provides Amphadase, a bovine-sourced hyaluronidase injection; Epinephrine injection for allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products; morphine injection for use with patient-controlled analgesia pumps; and Lorazepam injection for surgery and medical procedures.
Amphastar Pharmaceuticals, Inc. Fundamentals Summary
| 29A fundamental statistics | |
|---|---|
| Market cap | €1.01b |
| Earnings (TTM) | €140.46m |
| Revenue (TTM) | €644.50m |
7.3x
P/E Ratio1.6x
P/S RatioIs 29A overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 29A income statement (TTM) | |
|---|---|
| Revenue | US$731.97m |
| Cost of Revenue | US$358.11m |
| Gross Profit | US$373.86m |
| Other Expenses | US$214.34m |
| Earnings | US$159.52m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 3.35 |
| Gross Margin | 51.08% |
| Net Profit Margin | 21.79% |
| Debt/Equity Ratio | 82.1% |
How did 29A perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/04/14 03:46 |
| End of Day Share Price | 2025/04/14 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Amphastar Pharmaceuticals, Inc. is covered by 11 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Gary Nachman | BMO Capital Markets Equity Research |
| Jason Matthew Gerberry | BofA Global Research |
| Timothy Chiang | Capital One Securities, Inc. |